Cover Image
市場調查報告書

全球製藥產業相關分析

Analyzing the Global Pharmaceutical Industry 2015

出版商 Aruvian's R'search 商品編碼 221368
出版日期 內容資訊 英文 900 Pages
訂單完成後即時交付
價格
Back to Top
全球製藥產業相關分析 Analyzing the Global Pharmaceutical Industry 2015
出版日期: 2015年02月01日 內容資訊: 英文 900 Pages
簡介

現在,美國、歐洲、日本的大企業佔全球醫藥品市場大半,領導市場。另一方面,新興國家市場人口增加對全球製藥產業的成長有很大的貢獻。

本報告提供全球的製藥產業調查分析、整體產業結構、趨勢,及活躍活動的市場區隔、近幾年的主要趨勢(競爭、投資活動、知識產權的保護、各種的CSR活動等)、主要國家市場詳細趨勢(市場概況、各分類市場佔有率、競爭情形、今後的方向性)、主要企業簡介等相關彙整,為您概述為以下內容。

摘要整理

第1章 全球製藥產業相關分析

  • 全球製藥產業的歷史展望
  • 全球製藥產業分析
    • 定義
    • 統計
    • 市場區隔
    • 市場佔有率分析
    • 競爭
    • 市場預測
  • 全球製藥產業:波特的五力分析
  • 全球成藥產業分析
  • 全球成藥產業:波特的五力分析
  • 全球學名藥產業分析
  • 全球學名藥產業:波特的五力分析
  • 產業結構
    • 研究開發平台
    • 防禦學名藥
    • 重組和外包
    • 策略性聯盟
  • 產業分析
    • 進入障礙
    • 醫藥品的生命週期
    • 成本結構
    • 產業趨勢
    • 商業環境
    • 產業的創新
    • 製藥產業的全球化
    • 基因學扮演的角色
  • 全球製藥產業的成長促進及變革因素
    • 簡介
    • 製藥市場成長
    • 新產品線
    • 中樞神經系統障礙及腫瘤研究的機會
    • 休眠化合物的商品化
    • 生技藥品的非專利/生技仿製藥版
  • 全球製藥產業所面臨的課題
    • 並進交易
    • 醫療費的上升
    • 對產業收益的強烈壓力
    • 開發平台的不確定性
    • 風險的增加
    • 以結果為基礎的價格設定
    • 醫藥品開發轉移至開發中國家
    • 治療線減少策略的焦點
    • 代替內部開發的化合物的取得和授權
  • 全球性藥價、投資方案分析
    • 為何各企業尋求著價格設定的機會
    • 價格設定的獎勵
    • 並進交易的登場
    • 政府的目的
    • 恰當的價格設與定競爭
    • 醫藥品的可得性
    • 對有用的藥物的投資的優惠策略
    • 全球通用的成本和「free ride」的概念
  • 與知識產權的貿易相關的方面相關協定(TRIPS協定)全球製藥市場
    • 簡介
    • 產品專利和醫藥品的價格
    • 產品專利與研究開發(R&D)
    • 專利和技術轉移
    • 契約的彈性
    • 美國相關的問題
  • 製藥部門的境外外包
    • 簡介
    • 研究開發(R&D)活動的境外外包
    • 醫藥品製造工程的境外外包

第2章 全球各國的製藥市場相關分析

  • 澳洲
  • 比利時
  • 巴西
  • 加拿大
  • 中國
  • 捷克
  • 丹麥
  • 法國
  • 德國
  • 匈牙利
  • 印度
  • 義大利
  • 日本
  • 墨西哥
  • 荷蘭
  • 紐西蘭
  • 挪威
  • 波蘭
  • 俄羅斯
  • 新加坡
  • 南非
  • 韓國
  • 西班牙
  • 瑞典
  • 台灣
  • 英國
  • 美國

第3章 主要企業相關分析

  • Abbott Laboratories
  • Altana AG
  • Amgen
  • Apotex, Inc.
  • Aspen Pharmacare Holdings Limited
  • Astellas Pharma Inc.
  • AstraZeneca
  • Baxter International
  • Bayer AG
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • 中外製藥
  • Daewoong Pharmaceutical Co Ltd.
  • 第一三共
  • Eisai
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • Hoffmann-La Roche
  • GlaxoSmithKline
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co.
  • Piramal Healthcare
  • Novartis AG
  • Pfizer
  • Richter Gedeon Vegyeszeti Gyar Nyrt
  • Sanofi SA
  • Shanghai Pharmaceuticals Holding Co. Ltd.
  • 大日本住友製藥
  • 武田藥品工業
  • Teva Pharmaceutical Industries
  • Aurobindo Pharma Ltd
  • Cadila Healthcare
  • China National Accord Medicines Corporation Ltd
  • Cipla Ltd
  • Dr. Reddy's Laboratories Limited
  • Hanmi Science Co Ltd
  • Harbin Pharmaceutical Group Co. Ltd.
  • Jubilant Life Sciences Ltd
  • Mylan Laboratories Ltd
  • Pharmstandard OJSC
  • Ranbaxy Laboratories
  • Sun Pharmaceutical Industries
  • 大正製藥
  • Chiesi Farmaceutici SpA
  • Dong-A Pharmaceutical Co. Ltd
  • Jiangsu Yangtze River Pharmaceutical Group Co., Ltd
  • Yunnan Baiyao Group

第4章 用語

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

The global presence of the pharmaceutical industry is evident with the roll out of continent specific R&D programs and drugs which help companies maximize penetration of markets and garner increased revenues with intercontinental treatment demand of patients being serviced from often one or two mega research centers in the continent.

By contribution of size, the pharmaceutical industry is majorly dominant at the US, Asia Pacific. Led by these markets, the total world consumption in sales of pharmaceutical products has displayed strong growth and is expected to grow further with expanding populations in emerging markets.

However, in recent times, austerity measures across the world along with many countires imposing cutbacks on healthcare spending (particularly in Europe), has hit the pharmaceutical industry. Furthermore, the loss of patent for many blockbuster drugs during the years 2010-2015 is also going to have a big impact on the global pharmaceutical industry. However, generic manufacturers are likely to benefit from this as they are poised to capture a substantial portion of revenues with their generic versions of these drugs.

Aruvian's Research's report - ‘Analyzing the Global Pharmaceutical Industry’ - presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018.

The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy - store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat.

We analyze the global pharmaceutical industry, the global OTC market and the global generics industry through a Porter's Five Forces Framework analysis.

We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry.

Industry structure is analyzed through a look at research and development pipelines, defense against generic competition, restructuring and outsourcing as well as the formation of strategic alliances. Analyzing the global pharmaceutical industry further, we take a look at the barriers to entry facing the industry, lifecycle of a drug, industry cost structure, industry trends and innovation, business environment and globalization of the global pharmaceutical industry.

Factors driving growth and change in the global pharmaceutical industry are analyzed. Analyzed factors include the emergence of new product lines, reasons for industry growth, opportunities in various CNS disorders and oncology research, ongoing commercialization of dormant compounds along with a look at the role of biosimilars in the industry. Moving on, we also analyzed the various challenges facing the global pharmaceutical industry and how the industry is dealing with them.

The TRIPS agreement has been a point of debate in the globally wherein the issues are equally contested for the developing as well as the developed countries and the options of flexibility which have inculcated in the report are explained in this report. Apart from this, another interesting phenomenon explained in this report is the practice of “offshoring” amongst the pharma companies and the value chains which have been developed to service them globally.

An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018.

A total of 27 markets analyzed in our report include:

  • Australia
  • Belgium
  • Brazil
  • Canada
  • China
  • Czech Republic
  • Denmark
  • France
  • Germany
  • Hungary
  • India
  • Italy
  • Japan
  • Mexico
  • Netherlands
  • New Zealand
  • Norway
  • Poland
  • Russia
  • Singapore
  • South Africa
  • South Korea
  • Spain
  • Sweden
  • Taiwan
  • United Kingdom
  • United States

Moving on, a comprehensive analysis of the major industry players is undertaken. The players are analyzed through a corporate profile, an analysis of their major business segments, a financial analysis, ratio analysis, a look at their major products & services as well as a SWOT analysis. A total of 46 companies in our report.

With over 200 figures & tables, this highly insightful and analytical report from Aruvian Research is a complete & up-to-date coverage of the Global Pharmaceutical Industry.

Table of Contents

Executive Summary

Section 1: Analyzing the Global Pharmaceutical Industry

A. Historical Perspective of the Global Pharmaceutical Industry

B. Analysis of the Global Pharmaceutical Industry

  • B.1. Industry Definitions
    • B.1.1. Pharmaceutical Industry
    • B.1.2. Bulk Drugs
    • B.1.3. Formulations
  • B.2. Industry Statistics
  • B.3. Industry Value Analysis
  • B.4. Market Segments
  • B.5. Market Share Analysis
  • B.6. Competition in the Industry
  • B.7. Market Forecast

C. Global Pharmaceutical Industry: Porter's Five Forces Strategy Analysis

  • C.1. Introduction
  • C.2. Bargaining Power of Buyers
  • C.3. Bargaining Power of Suppliers
  • C.4. Competitive Rivalry in the Industry
  • C.5. Threat of New Entrants
  • C.6. Threat of Substitutes

D. Analysis of the Global OTC Pharmaceutical Industry

  • D.1. Industry Definition
  • D.2. Industry Statistics
  • D.3. Industry Value Analysis
  • D.4. Market Segments
  • D.5. Distribution Channels
  • D.6. Market Share Analysis
  • D.7. Market Forecast

E. Global OTC Pharmaceutical Industry: Porter's Five Forces Strategy Analysis

  • E.1. Introduction
  • E.2. Bargaining Power of Buyers
  • E.3. Bargaining Power of Suppliers
  • E.4. Competitive Rivalry in the Industry
  • E.5. Threat of New Entrants
  • E.6. Threat of Substitutes

F. Analysis the Global Generics Industry

  • F.1. Industry Definition
  • F.2. Industry Statistics
  • F.3. Industry Value & Volume Analysis
  • F.4. Market Segments
  • F.5. Industry Structure
  • F.6. Patent Expiries
  • F.7. Patent Expiries by Therapeutic Areas
  • F.8. Research & Development in the Industry
    • F.8.1. Super Generics
    • F.8.2. Biosimilars
  • F.9. Market Forecast

G. Global Generics Industry: Porter's Five Forces Strategy Analysis

  • G.1. Introduction
  • G.2. Bargaining Power of Buyers
  • G.3. Bargaining Power of Suppliers
  • G.4. Competitive Rivalry in the Industry
  • G.5. Threat of New Entrants
  • G.6. Threat of Substitutes

H. Structure of the Global Pharmaceutical Industry

  • H.1. R&D Pipelines
  • H.2. Defense against Generic Competition
  • H.3. Looking at Restructuring and Outsourcing
  • H.4. Strategic Alliances

I. Analyzing the Industry

  • I.1. Barriers to Entry
  • I.2. Lifecycle of a Drug
    • I.2.1. The Patent System
    • I.2.2. Drug Lifecycle
  • I.3. Industry Cost Structure
    • I.3.1. Types of Costs
    • I.3.2. Evidence on Cost Structure
    • I.3.3. Increasing Costs & Risks of Developing New Drugs
    • I.3.4. Conclusion
  • I.4. Trends in the Global Pharmaceutical Industry
  • I.5. Business Environment
  • I.6. Industry Innovation
  • I.7. Globalization of the Pharmaceutical Industry
  • I.8. Role of Genomics

J. Factors Driving Growth & Change in the Global Pharmaceutical Industry

  • J.1. Introduction
  • J.2. Growth in the Pharma Market
  • J.3. Reasons for Growth
  • J.4. New Product Lines
  • J.5. Opportunities in CNS Disorders & Oncology Research
  • J.6. Commercialization of Dormant Compounds
  • J.7. Generic/Biosimilar Versions of Biologics

K. Challenges Facing the Global Pharmaceutical Industry

  • K.1. Parallel Trade
  • K.2. Rising Cost of Healthcare
  • K.3. Immense Pressure on Industry Revenues
  • K.4. Uncertainty in Pipeline
  • K.5. Increasing Risks
  • K.6. Issues with Outcome-based Pricing

N. Offshoring in the Pharmaceutical Sector

  • N.1. Introduction
    • N.1.1. What is Offshoring?
    • N.1.2. Analyzing the Pharma Value Chain
    • N.1.3. Employment Scenario of the Pharmaceutical Industry
    • N.1.4. Why Offshore?
    • N.1.5. Primary Offshoring Locations
  • N.2. Offshoring of R&D
    • N.2.1. India
    • N.2.2. China
    • N.2.3. Growth Factors
    • N.2.4. Challenges & Barriers to Offshoring R&D
  • N.3. Offshoring of Pharmaceutical Manufacturing Processes
    • N.3.1. Overview
    • N.3.2. Biologics Manufacturing
    • N.3.3. API Manufacturing
    • N.3.4. Final Dosage Manufacturing
    • N.3.5. Growth Factors
    • N.3.6. Challenges & Barriers to Offshoring Manufacturing Processes

Section 2: Analyzing the Global Pharmaceutical Markets

A. Pharmaceutical Industry in Australia

  • A.1. Industry Statistics
  • A.2. Industry Value Analysis
  • A.3. Geographic Segmentation
  • A.4. Industry Trends
  • A.5. Production Trends
  • A.6. Market Share Analysis
  • A.7. Competition in the Industry
  • A.8. Industry Outlook

B. Pharmaceutical Industry in Belgium

  • B.1. Industry Statistics
  • B.2. Industry Value Analysis
  • B.3. Geographic Segmentation
  • B.4. Market Share Analysis
  • B.5. Competition in the Industry
  • B.6. Industry Outlook

C. Pharmaceutical Industry in Brazil

  • C.1. Industry Statistics
  • C.2. Industry Value Analysis
  • C.3. Geographic Segmentation
  • C.4. Market Share Analysis
  • C.5. Competition in the Industry
  • C.6. Industry Outlook

D. Pharmaceutical Industry in Canada

  • D.1. Industry Statistics
  • D.2. Industry Value Analysis
  • D.3. Geographic Segmentation
  • D.4. Market Share Analysis
  • D.5. Competition in the Industry
  • D.6. Industry Outlook

E. Pharmaceutical Industry in China

  • E.1. Industry Statistics
  • E.2. Industry Value Analysis
  • E.3. Geographic Segmentation
  • E.4. Industry Trends
  • E.5. Production Trends
  • E.6. Regulatory Framework
  • E.7. Market for Traditional Chinese Medicine
  • E.8. Market Share Analysis
  • E.9. Competition in the Industry
  • E.10. Industry Outlook

F. Pharmaceutical Industry in Czech Republic

  • F.1. Industry Statistics
  • F.2. Industry Value Analysis
  • F.3. Geographic Segmentation
  • F.4. Market Share Analysis
  • F.5. Competition in the Industry
  • F.6. Industry Outlook

G. Pharmaceutical Industry in Denmark

  • G.1. Industry Statistics
  • G.2. Industry Value Analysis
  • G.3. Geographic Segmentation
  • G.4. Market Share Analysis
  • G.5. Competition in the Industry
  • G.6. Industry Outlook

H. Pharmaceutical Industry in France

  • H.1. Industry Statistics
  • H.2. Industry Value Analysis
  • H.3. Geographic Segmentation
  • H.4. Market Share Analysis
  • H.5. Competition in the Industry
  • H.6. Industry Outlook

I. Pharmaceutical Industry in Germany

  • I.1. Industry Statistics
  • I.2. Industry Value Analysis
  • I.3. Geographic Segmentation
  • I.4. Market Share Analysis
  • I.5. Competition in the Industry
  • I.6. Industry Outlook

J. Pharmaceutical Industry in Hungary

  • J.1. Industry Statistics
  • J.2. Industry Value Analysis
  • J.3. Geographic Segmentation
  • J.4. Market Share Analysis
  • J.5. Competition in the Industry
  • J.6. Industry Outlook
  • K. Pharmaceutical Industry in India
  • K.1. Industry Statistics
  • K.2. Industry Value Analysis
  • K.3. Geographic Segmentation
  • K.4. Industry Trends
  • K.5. Production Trends
  • K.6. Market Share Analysis
  • K.7. Competition in the Industry
  • K.8. Industry Outlook

L. Pharmaceutical Industry in Italy

  • L.1. Industry Statistics
  • L.2. Industry Value Analysis
  • L.3. Geographic Segmentation
  • L.4. Market Share Analysis
  • L.5. Competition in the Industry
  • L.6. Industry Outlook

M. Pharmaceutical Industry in Japan

  • M.1. Industry Statistics
  • M.2. Industry Value Analysis
  • M.3. Geographic Segmentation
  • M.4. Industry Trends
  • M.5. Production Trends
  • M.6. Market Share Analysis
  • M.7. Competition in the Industry
  • M.8. Industry Outlook

N. Pharmaceutical Industry in Mexico

  • N.1. Industry Statistics
  • N.2. Industry Value Analysis
  • N.3. Geographic Segmentation
  • N.4. Market Share Analysis
  • N.5. Competition in the Industry
  • N.6. Industry Outlook

O. Pharmaceutical Industry in Netherlands

  • O.1. Industry Statistics
  • O.2. Industry Value Analysis
  • O.3. Geographic Segmentation
  • O.4. Market Share Analysis
  • O.5. Competition in the Industry
  • O.6. Industry Outlook

P. Pharmaceutical Industry in New Zealand

  • P.1. Industry Statistics
  • P.2. Industry Value Analysis
  • P.3. Geographic Segmentation
  • P.4. Market Share Analysis
  • P.5. Competition in the Industry
  • P.6. Industry Outlook

Q. Pharmaceutical Industry in Norway

  • Q.1. Industry Statistics
  • Q.2. Industry Value Analysis
  • Q.3. Geographic Segmentation
  • Q.4. Market Share Analysis
  • Q.5. Competition in the Industry
  • Q.6. Industry Outlook

R. Pharmaceutical Industry in Poland

  • R.1. Industry Statistics
  • R.2. Industry Value Analysis
  • R.3. Geographic Segmentation
  • R.4. Market Share Analysis
  • R.5. Competition in the Industry
  • R.6. Industry Outlook

S. Pharmaceutical Industry in Russia

  • S.1. Industry Statistics
  • S.2. Industry Value Analysis
  • S.3. Geographic Segmentation
  • S.4. Market Share Analysis
  • S.5. Competition in the Industry
  • S.6. Industry Outlook

T. Pharmaceutical Industry in Singapore

  • T.1. Industry Statistics
  • T.2. Industry Value Analysis
  • T.3. Geographic Segmentation
  • T.4. Market Share Analysis
  • T.5. Competition in the Industry
  • T.6. Industry Outlook

U. Pharmaceutical Industry in South Africa

  • U.1. Industry Statistics
  • U.2. Industry Value Analysis
  • U.3. Geographic Segmentation
  • U.4. Market Share Analysis
  • U.5. Competition in the Industry
  • U.6. Industry Outlook

V. Pharmaceutical Industry in South Korea

  • V.1. Industry Statistics
  • V.2. Industry Value Analysis
  • V.3. Geographic Segmentation
  • V.4. Market Share Analysis
  • V.5. Competition in the Industry
  • V.6. Industry Outlook

W. Pharmaceutical Industry in Spain

  • W.1. Industry Statistics
  • W.2. Industry Value Analysis
  • W.3. Geographic Segmentation
  • W.4. Market Share Analysis
  • W.5. Competition in the Industry
  • W.6. Industry Outlook

X. Pharmaceutical Industry in Sweden

  • X.1. Industry Statistics
  • X.2. Industry Value Analysis
  • X.3. Geographic Segmentation
  • X.4. Market Share Analysis
  • X.5. Competition in the Industry
  • X.6. Industry Outlook

Y. Pharmaceutical Industry in Taiwan

  • Y.1. Industry Statistics
  • Y.2. Industry Value Analysis
  • Y.3. Geographic Segmentation
  • Y.4. Market Share Analysis
  • Y.5. Competition in the Industry
  • Y.6. Industry Outlook

Z. Pharmaceutical Industry in United Kingdom

  • Z.1. Industry Statistics
  • Z.2. Industry Value Analysis
  • Z.3. Geographic Segmentation
  • Z.4. Market Share Analysis
  • Z.5. Competition in the Industry
  • Z.6. Industry Outlook

AA. Pharmaceutical Industry in the United States

  • AA.1. Industry Statistics
  • AA.2. Industry Value Analysis
  • AA.3. Geographic Segmentation
  • AA.4. Market Share Analysis
  • AA.5. Competition in the Industry
  • AA.6. Industry Outlook

Section 3: Analyzing the Major Market Players

A. Abbott Laboratories

  • A.1. Corporate Profile
  • A.2. Business Segment Analysis
  • A.3. Financial Analysis
  • A.4. Ratio Analysis
  • A.5. Major Products & Services
  • A.6. SWOT Analysis

B. Allergan, Inc.

  • B.1. Corporate Profile
  • B.2. Business Segment Analysis
  • B.3. Financial Analysis
  • B.4. Ratio Analysis
  • B.5. Major Products & Services
  • B.6. SWOT Analysis

C. Amgen, Inc.

  • C.1. Corporate Profile
  • C.2. Business Segment Analysis
  • C.3. Financial Analysis
  • C.4. Ratio Analysis
  • C.5. Major Products & Services
  • C.6. SWOT Analysis

D. Apotex, Inc.

  • D.1. Corporate Profile
  • D.2. Business Segment Analysis
  • D.3. Financial Analysis
  • D.4. Ratio Analysis
  • D.5. Major Products & Services
  • D.6. SWOT Analysis

E. Aspen Pharmacare Holdings Limited

  • E.1. Corporate Profile
  • E.2. Business Segment Analysis
  • E.3. Financial Analysis
  • E.4. Ratio Analysis
  • E.5. Major Products & Services
  • E.6. SWOT Analysis

F. Astellas Pharma

  • F.1. Corporate Profile
  • F.2. Business Segment Analysis
  • F.3. Financial Analysis
  • F.4. Ratio Analysis
  • F.5. Major Products & Services
  • F.6. SWOT Analysis

G. AstraZeneca

  • G.1. Corporate Profile
  • G.2. Business Segment Analysis
  • G.3. Financial Analysis
  • G.4. Ratio Analysis
  • G.5. Major Products & Services
  • G.6. SWOT Analysis

H. Baxter International

  • H.1. Corporate Profile
  • H.2. Business Segment Analysis
  • H.3. Financial Analysis
  • H.4. Ratio Analysis
  • H.5. Major Products & Services
  • H.6. SWOT Analysis

I. Bayer AG

  • I.1. Corporate Profile
  • I.2. Business Segment Analysis
  • I.3. Financial Analysis
  • I.4. Ratio Analysis
  • I.5. Major Products & Services
  • I.6. SWOT Analysis

J. Boehringer Ingelheim

  • J.1. Corporate Profile
  • J.2. Business Segment Analysis
  • J.3. Financial Analysis
  • J.4. Ratio Analysis
  • J.5. Major Products & Services
  • J.6. SWOT Analysis

K. Bristol-Myers Squibb

  • K.1. Corporate Profile
  • K.2. Business Segment Analysis
  • K.3. Financial Analysis
  • K.4. Ratio Analysis
  • K.5. Major Products & Services
  • K.6. SWOT Analysis

L. Chugai Pharmaceutical

  • L.1. Corporate Profile
  • L.2. Business Segment Analysis
  • L.3. Financial Analysis
  • L.4. Ratio Analysis
  • L.5. Major Products & Services
  • L.6. SWOT Analysis

M. Daewoong Pharmaceutical Co Ltd.

  • M.1. Corporate Profile
  • M.2. Business Segment Analysis
  • M.3. Financial Analysis
  • M.4. Ratio Analysis
  • M.5. Major Products & Services
  • M.6. SWOT Analysis

N. Daiichi Sankyo Company

  • N.1. Corporate Profile
  • N.2. Business Segment Analysis
  • N.3. Financial Analysis
  • N.4. Ratio Analysis
  • N.5. Major Products & Services
  • N.6. SWOT Analysis

O. Eisai Co., Ltd

  • O.1. Corporate Profile
  • O.2. Business Segment Analysis
  • O.3. Financial Analysis
  • O.4. Ratio Analysis
  • O.5. Major Products & Services
  • O.6. SWOT Analysis

P. Eli Lilly and Company

  • P.1. Corporate Profile
  • P.2. Business Segment Analysis
  • P.3. Financial Analysis
  • P.4. Ratio Analysis
  • P.5. Major Products & Services
  • P.6. SWOT Analysis

Q. F. Hoffmann-La Roche

  • Q.1. Corporate Profile
  • Q.2. Business Segment Analysis
  • Q.3. Financial Analysis
  • Q.4. Ratio Analysis
  • Q.5. Major Products & Services
  • Q.6. SWOT Analysis

R. GlaxoSmithKline Plc

  • R.1. Corporate Profile
  • R.2. Business Segment Analysis
  • R.3. Financial Analysis
  • R.4. Ratio Analysis
  • R.5. Major Products & Services
  • R.6. SWOT Analysis

S. Johnson & Johnson

  • S.1. Corporate Profile
  • S.2. Business Segment Analysis
  • S.3. Financial Analysis
  • S.4. Ratio Analysis
  • S.5. Major Products & Services
  • S.6. SWOT Analysis

T. Lupin Limited

  • T.1. Corporate Profile
  • T.2. Business Segment Analysis
  • T.3. Financial Analysis
  • T.4. Ratio Analysis
  • T.5. Major Products & Services
  • T.6. SWOT Analysis

U. Merck & Co.

  • U.1. Corporate Profile
  • U.2. Business Segment Analysis
  • U.3. Financial Analysis
  • U.4. Ratio Analysis
  • U.5. Major Products & Services
  • U.6. SWOT Analysis

V. Novartis AG

  • V.1. Corporate Profile
  • V.2. Business Segment Analysis
  • V.3. Financial Analysis
  • V.4. Ratio Analysis
  • V.5. Major Products & Services
  • V.6. SWOT Analysis

W. Pfizer

  • W.1. Corporate Profile
  • W.2. Business Segment Analysis
  • W.3. Financial Analysis
  • W.4. Ratio Analysis
  • W.5. Major Products & Services
  • W.6. SWOT Analysis

X. Richter Gedeon Vegyeszeti Gyar Nyrt

  • X.1. Corporate Profile
  • X.2. Business Segment Analysis
  • X.3. Financial Analysis
  • X.4. Ratio Analysis
  • X.5. Major Products & Services
  • X.6. SWOT Analysis

Y. Sanofi SA

  • Y.1. Corporate Profile
  • Y.2. Business Segment Analysis
  • Y.3. Financial Analysis
  • Y.4. Ratio Analysis
  • Y.5. Major Products & Services
  • Y.6. SWOT Analysis

Z. Shanghai Pharmaceuticals Holding Co. Ltd.

  • Z.1. Corporate Profile
  • Z.2. Business Segment Analysis
  • Z.3. Financial Analysis
  • Z.4. Ratio Analysis
  • Z.5. Major Products & Services
  • Z.6. SWOT Analysis

AA. Sumitomo Dainippon Pharma

  • AA.1. Corporate Profile
  • AA.2. Business Segment Analysis
  • AA.3. Financial Analysis
  • AA.4. Ratio Analysis
  • AA.5. Major Products & Services
  • AA.6. SWOT Analysis

BB. Takeda Pharmaceutical Company Limited

  • BB.1. Corporate Profile
  • BB.2. Business Segment Analysis
  • BB.3. Financial Analysis
  • BB.4. Ratio Analysis
  • BB.5. Major Products & Services
  • BB.6. SWOT Analysis

CC. Teva Pharmaceutical Industries

  • CC.1. Corporate Profile
  • CC.2. Business Segment Analysis
  • CC.3. Financial Analysis
  • CC.4. Ratio Analysis
  • CC.5. Major Products & Services
  • CC.6. SWOT Analysis

DD. Aurobindo Pharma Ltd

  • DD.1. Corporate Profile
  • DD.2. Business Segment Analysis
  • DD.3. Financial Analysis
  • DD.4. Ratio Analysis
  • DD.5. Major Products & Services

EE. Cadila Healthcare

  • EE.1. Corporate Profile
  • EE.2. Business Segment Analysis
  • EE.3. Financial Analysis
  • EE.4. Ratio Analysis
  • EE.5. Major Products & Services

FF. China National Accord Medicines Corporation Ltd

  • FF.1. Corporate Profile
  • FF.2. Business Segment Analysis
  • FF.3. Financial Analysis
  • FF.4. Ratio Analysis
  • FF.5. Major Products & Services

GG. Cipla Ltd

  • GG.1. Corporate Profile
  • GG.2. Business Segment Analysis
  • GG.3. Financial Analysis
  • GG.4. Ratio Analysis
  • GG.5. Major Products & Services

HH. Dr. Reddy's Laboratories Limited

  • HH.1. Corporate Profile
  • HH.2. Business Segment Analysis
  • HH.3. Financial Analysis
  • HH.4. Ratio Analysis
  • HH.5. Major Products & Services

II. Hanmi Science Co Ltd

  • II.1. Corporate Profile
  • II.2. Business Segment Analysis
  • II.3. Financial Analysis
  • II.4. Ratio Analysis
  • II.5. Major Products & Services

JJ. Harbin Pharmaceutical Group Co. Ltd.

  • JJ.1. Corporate Profile
  • JJ.2. Business Segment Analysis
  • JJ.3. Financial Analysis
  • JJ.4. Ratio Analysis
  • JJ.5. Major Products & Services

KK. Jubilant Life Sciences Ltd

  • KK.1. Corporate Profile
  • KK.2. Business Segment Analysis
  • KK.3. Financial Analysis
  • KK.4. Ratio Analysis
  • KK.5. Major Products & Services

LL. Mylan Laboratories Ltd

  • LL.1. Corporate Profile
  • LL.2. Business Segment Analysis
  • LL.3. Financial Analysis
  • LL.4. Ratio Analysis
  • LL.5. Major Products & Services

MM. Pharmstandard OJSC

  • MM.1. Corporate Profile
  • MM.2. Business Segment Analysis
  • MM.3. Financial Analysis
  • MM.4. Ratio Analysis
  • MM.5. Major Products & Services

NN. Ranbaxy Laboratories

  • NN.1. Corporate Profile
  • NN.2. Business Segment Analysis
  • NN.3. Financial Analysis
  • NN.4. Ratio Analysis
  • NN.5. Major Products & Services

OO. Sun Pharmaceutical Industries

  • OO.1. Corporate Profile
  • OO.2. Business Segment Analysis
  • OO.3. Financial Analysis
  • OO.4. Ratio Analysis
  • OO.5. Major Products & Services

PP. Taisho Pharmaceutical Co., Ltd.

  • PP.1. Corporate Profile
  • PP.2. Business Segment Analysis
  • PP.3. Financial Analysis
  • PP.4. Ratio Analysis
  • PP.5. Major Products & Services

QQ. Chiesi Farmaceutici SpA

RR. Dong-A Pharmaceutical Co. Ltd

SS. Jiangsu Yangtze River Pharmaceutical Group Co., Ltd.

TT. Yunnan Baiyao Group

Section 4: Glossary of Terms

List of Figures

  • Figure 1: Value of the Global Pharmaceutical Industry (in USD Billion), 2009-2013
  • Figure 2: Segmentation of the Global Pharmaceutical Industry by Regions (%), 2013
  • Figure 3: Market Share of the Global Pharmaceutical Industry (%), 2013
  • Figure 4: Forecast of the Global Pharmaceutical Industry (in USD Billion), 2013-2018
  • Figure 5: Porter's Five Forces Analysis of the Global Pharmaceutical Industry
  • Figure 6: Buyer Power in the Global Pharmaceutical Industry
  • Figure 7: Supplier Power in the Global Pharmaceutical Industry
  • Figure 8: Rivalry in the Global Pharmaceutical Industry
  • Figure 9: Threat of New Entrants in the Global Pharmaceutical Industry
  • Figure 10: Threat of Substitutes in the Global Pharmaceutical Industry
  • Figure 11: Value of the Global OTC Pharmaceutical Industry (in USD Million), 2009-2013
  • Figure 12: Segmentation of the Global OTC Pharmaceutical Market by Categories (%), 2013
  • Figure 13: Segmentation of the Global OTC Pharmaceutical Market by Regions (%), 2013
  • Figure 14: Major Distribution Channels in the Global OTC Pharma Market (%), 2013
  • Figure 15: Market Share of the Global Pharmaceutical Industry (%), 2013
  • Figure 16: Forecast of the Global OTC Pharmaceutical Industry (in USD Million), 2013-2018
  • Figure 17: Porter's Five Forces Analysis of the Global OTC Pharmaceutical Industry
  • Figure 18: Buyer Power in the Global OTC Pharmaceutical Industry
  • Figure 19: Supplier Power in the Global OTC Pharmaceutical Industry
  • Figure 20: Competition in the Global OTC Pharmaceutical Industry
  • Figure 21: Threat of New Entrants in the Global OTC Pharmaceutical Industry
  • Figure 22: Threat of Substitutes in the Global OTC Pharmaceutical Industry
  • Figure 23: Historical Revenues of Leading Generic Companies (in USD Million), 2008-2009
  • Figure 24: Generics Percentage of Total Pharmaceutical Volume & Market Volume of Global Generics Industry (%), 2009-2013
  • Figure 25: Global Generics Market Segmentation by Geography (%), 2013
  • Figure 26: Market Share of Leading Generic Companies Worldwide (%), 2013
  • Figure 27: Comparison of Revenues of Leading Generic Companies (in USD Million), 2011-2012
  • Figure 28: Revenues of Top 10 Drugs Facing Patent Expiries between 2010-2014 (in USD Million)
  • Figure 29: Value of Drugs to Lose Patent Protection during 2010-2014 by Therapeutic Area (%)
  • Figure 30: Global Generics Industry Forecast (in USD Million), 2013-2018
  • Figure 31: Global Generics Industry Forecast by Volume (%), 2013-2018
  • Figure 32: Porter's Five Forces Analysis of the Global Generics Industry
  • Figure 33: Buyer Power in the Global Generics Industry
  • Figure 34: Supplier Power in the Global Generics Industry
  • Figure 35: Competition in the Global Generics Industry
  • Figure 36: Threat of New Entrants in the Global Generics Industry
  • Figure 37: Threat of Substitutes in the Global Generics Industry
  • Figure 38: Lifecycle of a Drug: from Patent to Patient
  • Figure 39: Trends in R&D to Sales Ratio, 1970-2000
  • Figure 40: Factors Impacting the Growth of the Pharma Industry
  • Figure 41: Factors Restraining the Pharma Market
  • Figure 42: Healthcare Expenditure as a Percentage of GDP in the US, 1960-2010
  • Figure 43: Number of Compounds to Produce a New Drug
  • Figure 44: Expense of Clinical Trials in Emerging Markets
  • Figure 45: Offshoring Business Models
  • Figure 46: Pharmaceutical Value Chain
  • Figure 47: Global Pharmaceutical Employment by Region (%), 2013
  • Figure 48: Global Pharmaceutical Employment by Segment (%), 2013
  • Figure 49: MPCs' R&D Activities in India
  • Figure 50: India's Pharmaceutical R&D Environment
  • Figure 51: China's Pharmaceutical R&D Environment
  • Figure 52: Comparing Pharmaceutical R&D Capabilities between China and India
  • Figure 53: Advantages of Conducting Clinical Trials in China and India
  • Figure 54: Comparing Costs of Formulation Manufacturing between USA and India
  • Figure 55: Breakdown of Formulation Manufacturing Cost Advantage in India
  • Figure 56: Value of the Pharmaceutical Industry in Australia (in USD Billion), 2009-2013
  • Figure 57: Share of Australia in the Asia Pacific Pharmaceutical Industry (%), 2013
  • Figure 58: Market Share of the Australian Pharmaceutical Industry (%), 2013
  • Figure 59: Forecast of the Pharmaceutical Industry in Australia (in USD Billion), 2013-2018
  • Figure 60: Value of the Pharmaceutical Industry in Belgium (in USD Billion), 2009-2013
  • Figure 61: Share of Belgium in the European Pharmaceutical Industry (%), 2013
  • Figure 62: Market Share of the Belgian Pharmaceutical Industry (%), 2013
  • Figure 63: Forecast of the Pharmaceutical Industry in Belgium (in USD Billion), 2013-2018
  • Figure 64: Value of the Pharmaceutical Industry in Brazil (in USD Billion), 2009-2013
  • Figure 65: Share of Brazil in the Americas Pharmaceutical Industry (%), 2013
  • Figure 66: Market Share of the Global Pharmaceutical Industry (%), 2013
  • Figure 67: Forecast of the Pharmaceutical Industry in Brazil (in USD Billion), 2013-2018
  • Figure 68: Value of the Pharmaceutical Industry in Canada (in USD Billion), 2009-2013
  • Figure 69: Share of Canada in the Americas Pharmaceutical Industry (%), 2013
  • Figure 70: Market Share of the Canadian Pharmaceutical Industry (%), 2013
  • Figure 71: Forecast of the Pharmaceutical Industry in Canada (in USD Billion), 2013-2018
  • Figure 72: Total Asset of Pharmaceutical Industry in China, 2004-2013
  • Figure 73: Revenue and Net Profit Margin of Pharmaceutical Industry in China, 2006-2013
  • Figure 74: China's Pharmaceutical Industry Revenue by Product Category (%), 2013
  • Figure 75: Pharmaceutical Market by Therapeutic Area (%), 2013
  • Figure 76: Value of the Pharmaceutical Industry in China (in USD Billion), 2009-2013
  • Figure 77: Share of China in the Asia Pacific Pharmaceutical Industry (%), 2013
  • Figure 78: Revenue of Traditional Chinese Medicine (in RMB Billion), 2002-2013
  • Figure 79: Market Share of the Chinese Pharmaceutical Industry (%), 2013
  • Figure 80: Forecast of the Pharmaceutical Industry in China (in USD Billion), 2013-2018
  • Figure 81: Value of the Pharmaceutical Industry in Czech Republic (in USD Billion), 2009-2013
  • Figure 82: Share of Czech Republic in the European Pharmaceutical Industry (%), 2013
  • Figure 83: Market Share of the Czech Republic Pharmaceutical Industry (%), 2013
  • Figure 84: Forecast of the Czech Republic Pharmaceutical Industry (in USD Billion), 2013-2018
  • Figure 85: Value of the Pharmaceutical Industry in Denmark (in USD Billion), 2009-2013
  • Figure 86: Share of Denmark in the European Pharmaceutical Industry (%), 2013
  • Figure 87: Market Share of the Danish Pharmaceutical Industry (%), 2013
  • Figure 88: Forecast of the Pharmaceutical Industry in Denmark (in USD Billion), 2013-2018
  • Figure 89: Value of the Pharmaceutical Industry in France (in USD Billion), 2009-2013
  • Figure 90: Share of France in the European Pharmaceutical Industry (%), 2013
  • Figure 91: Market Share of the French Pharmaceutical Industry (%), 2013
  • Figure 92: Forecast of the Pharmaceutical Industry in France (in USD Billion), 2013-2018
  • Figure 93: Value of the Pharmaceutical Industry in Germany (in USD Billion), 2009-2013
  • Figure 94: Share of Germany in the European Pharmaceutical Industry (%), 2013
  • Figure 95: Market Share Analysis of the German Pharmaceutical Industry (%), 2013
  • Figure 96: Forecast of the Pharmaceutical Industry in Germany (in USD Billion), 2013-2018
  • Figure 97: Value of the Pharmaceutical Industry in Hungary (in USD Billion), 2009-2013
  • Figure 98: Share of Hungary in the European Pharmaceutical Industry (%), 2013
  • Figure 99: Market Share of the Hungarian Pharmaceutical Industry (%), 2013
  • Figure 100: Forecast of the Pharmaceutical Industry in Hungary (in USD Billion), 2013-2018
  • Figure 101: Value of the Pharmaceutical Industry in India (in USD Billion), 2009-2013
  • Figure 102: Share of India in the Asia Pacific Pharmaceutical Industry (%), 2013
  • Figure 103: Market Share of the Indian Pharmaceutical Industry (%), 2013
  • Figure 104: Forecast of the Pharmaceutical Industry in India (in USD Billion), 2013-2018
  • Figure 105: Value of the Pharmaceutical Industry in Italy (in USD Billion), 2009-2013
  • Figure 106: Share of Italy in the European Pharmaceutical Industry (%), 2013
  • Figure 107: Market Share of the Italian Pharmaceutical Industry (%), 2013
  • Figure 108: Forecast of the Pharmaceutical Industry in Italy (in USD Billion), 2013-2018
  • Figure 109: Value of the Pharmaceutical Industry in Japan (in USD Billion), 2009-2013
  • Figure 110: Share of Japan in the Asia Pacific Pharmaceutical Industry (%), 2013
  • Figure 111: Market Share of the Japanese Pharmaceutical Industry (%), 2013
  • Figure 112: Forecast of the Pharmaceutical Industry in Japan (in USD Billion), 2013-2018
  • Figure 113: Value of the Pharmaceutical Industry in Mexico (in USD Billion), 2009-2013
  • Figure 114: Share of Mexico in the Americas Pharmaceutical Industry (%), 2013
  • Figure 115: Market Share of the Mexican Pharmaceutical Industry (%), 2013
  • Figure 116: Forecast of the Pharmaceutical Industry in Mexico (in USD Billion), 2013-2018
  • Figure 117: Value of the Dutch Pharmaceutical Industry (in USD Billion), 2009-2013
  • Figure 118: Share of Netherlands in the European Pharmaceutical Industry (%), 2013
  • Figure 119: Market Share of the Netherlands Pharmaceutical Industry (%), 2013
  • Figure 120: Forecast of the Netherlands Pharmaceutical Industry (in USD Billion), 2013-2018
  • Figure 121: Value of the New Zealand Pharmaceutical Industry (in USD Billion), 2009-2013
  • Figure 122: Share of New Zealand in the Asia Pacific Pharmaceutical Industry (%), 2013
  • Figure 123: Market Share of the New Zealand Pharmaceutical Industry (%), 2013
  • Figure 124: Forecast of the New Zealand Pharmaceutical Industry (in USD Billion), 2013-2018
  • Figure 125: Value of the Pharmaceutical Industry in Norway (in USD Billion), 2009-2013
  • Figure 126: Share of Norway in the European Pharmaceutical Industry (%), 2013
  • Figure 127: Market Share of the Norwegian Pharmaceutical Industry (%), 2013
  • Figure 128: Value of the Pharmaceutical Industry in Norway (in USD Billion), 2009-2013
  • Figure 129: Value of the Pharmaceutical Industry in Poland (in USD Billion), 2009-2013
  • Figure 130: Share of Poland in the European Pharmaceutical Industry (%), 2013
  • Figure 131: Market Share of the Polish Pharmaceutical Industry (%), 2013
  • Figure 132: Forecast of the Pharmaceutical Industry in Poland (in USD Billion), 2013-2018
  • Figure 133: Value of the Pharmaceutical Industry in Russia (in USD Billion), 2009-2013
  • Figure 134: Share of Russia in the European Pharmaceutical Industry (%), 2013
  • Figure 135: Market Share of the Russian Pharmaceutical Industry (%), 2013
  • Figure 136: Forecast of the Pharmaceutical Industry in Russia (in USD Billion), 2013-2018
  • Figure 137: Value of the Pharmaceutical Industry in Singapore (in USD Billion), 2009-2013
  • Figure 138: Share of Singapore in the Asia Pacific Pharmaceutical Industry (%), 2013
  • Figure 139: Market Share of the Singaporean Pharmaceutical Industry (%), 2013
  • Figure 140: Forecast of the Pharmaceutical Industry in Singapore (in USD Billion), 2013-2018
  • Figure 141: Value of the Pharmaceutical Industry in South Africa (in USD Billion), 2009-2013
  • Figure 142: Share of South Africa in the MEA Pharmaceutical Industry (%), 2013
  • Figure 143: Market Share of the South African Pharmaceutical Industry (%), 2013
  • Figure 144: Forecast of the Pharmaceutical Industry in South Africa (in USD Billion), 2013-2018
  • Figure 145: Value of the Pharmaceutical Industry in South Korea (in USD Billion), 2009-2013
  • Figure 146: Share of South Korea in the Asia Pacific Pharmaceutical Industry (%), 2013
  • Figure 147: Market Share of the South Korean Pharmaceutical Industry (%), 2013
  • Figure 148: Forecast of the Pharmaceutical Industry in South Korea (in USD Billion), 2013-2018
  • Figure 149: Value of the Pharmaceutical Industry in Spain (in USD Billion), 2009-2013
  • Figure 150: Share of Spain in the European Pharmaceutical Industry (%), 2013
  • Figure 151: Market Share of the Spanish Pharmaceutical Industry (%), 2013
  • Figure 152: Forecast of the Pharmaceutical Industry in Spain (in USD Billion), 2013-2018
  • Figure 153: Value of the Pharmaceutical Industry in Sweden (in USD Billion), 2009-2013
  • Figure 154: Share of Sweden in the European Pharmaceutical Industry (%), 2013
  • Figure 155: Market Share of the Swedish Pharmaceutical Industry (%), 2013
  • Figure 156: Forecast of the Pharmaceutical Industry in Sweden (in USD Billion), 2013-2018
  • Figure 157: Value of the Pharmaceutical Industry in Taiwan (in USD Billion), 2009-2013
  • Figure 158: Share of Taiwan in the Asia Pacific Pharmaceutical Industry (%), 2013
  • Figure 159: Market Share of the Taiwanese Pharmaceutical Industry (%), 2013
  • Figure 160: Forecast of the Pharmaceutical Industry in Taiwan (in USD Billion), 2013-2018
  • Figure 161: Value of the Pharmaceutical Industry in UK (in USD Billion), 2009-2013
  • Figure 162: Share of UK in the European Pharmaceutical Industry (%), 2013
  • Figure 163: Market Share of the UK Pharmaceutical Industry (%), 2013
  • Figure 164: Forecast of the UK Pharmaceutical Industry (in USD Billion), 2013-2018
  • Figure 165: Value of the US Pharmaceutical Industry (in USD Billion), 2009-2013
  • Figure 166: Share of United States in the Global Pharmaceutical Industry (%), 2013
  • Figure 167: Market Share of the US Pharmaceutical Industry (%), 2013
  • Figure 168: Forecast of the US Pharmaceutical Industry (in USD Billion), 2013-2018
  • Figure 169: Financial Performance of Abbott Laboratories (in USD Million), 2009-2013
  • Figure 170: Financial Performance of Allergan, Inc. (in USD Million), 2009-2013
  • Figure 171: Financial Performance of Amgen Inc. (in USD Million), 2009-2013
  • Figure 172: Financial Performance of Aspen Pharmacare (in ZAR Million), 2010-2014
  • Figure 173: Financial Performance of Astellas Pharma (in JPY Million), 2010-2014
  • Figure 174: Financial Performance of AstraZeneca Plc (in USD Million), 2009-2013
  • Figure 175: Financial Performance of Baxter International (in USD Million), 2009-2013
  • Figure 176: Financial Performance of Bayer AG (in USD Million), 2009-2013
  • Figure 177: Financial Performance of Bristol-Myers Squibb (in USD Million), 2009-2013
  • Figure 178: Financial Performance of Chugai Pharmaceutical (in JPY Million), 2009-2013
  • Figure 179: Financial Performance of Daewoong Pharmaceutical (in KRW Million), 2009-2013
  • Figure 180: Financial Performance of Daiichi Sankyo Company (in JPY Million), 2010-2014
  • Figure 181: Financial Performance of Eisai Co. (in JPY Million), 2010-2014
  • Figure 182: Financial Performance of Eli Lilly and Company (in USD Million), 2009-2013
  • Figure 183: Financial Performance of F. Hoffmann-La Roche (in CHF Million), 2009-2013
  • Figure 184: Financial Performance of GlaxoSmithKline (in GBP Million), 2009-2013
  • Figure 185: Financial Performance of Johnson & Johnson (in USD Million), 2009-2013
  • Figure 186: Financial Performance of Lupin (in INR Million), 2010-2014
  • Figure 187: Financial Performance of Merck & Co. (in USD Million), 2009-2013
  • Figure 188: Financial Performance of Novartis AG (in USD Million), 2009-2013
  • Figure 189: Financial Performance of Pfizer (in USD Million), 2009-2013
  • Figure 190: Financial Performance of Richter Gedeon Vegyeszeti Gyar Nyrt (in HUF Million), 2009-2013
  • Figure 191: Financial Performance of Sanofi SA (in EUR Million), 2009-2013
  • Figure 192: Financial Performance of Shanghai Pharmaceuticals (in CNY Million), 2009-2013
  • Figure 193: Financial Performance of Sumitomo Dainippon Pharma (in JPY Million), 2010-2014
  • Figure 194: Financial Performance of Takeda Pharmaceutical Company (in USD Million), 2010-2014
  • Figure 195: Financial Performance of Teva Pharmaceutical Industries (in USD Million), 2009-2013
  • Figure 196: Financial Performance of Aurobindo Pharma (in INR Million), 2010-2014
  • Figure 197: Financial Performance of Cadila Healthcare (in INR Million), 2010-2014
  • Figure 198: Financial Performance of China National Accord Medicines Corporation (in USD Million), 2008-2012
  • Figure 199: Financial Performance of Cipla Ltd. (in INR Million), 2009-2013
  • Figure 200: Financial Performance of Dr. Reddy's Laboratories (in INR Million), 2010-2014
  • Figure 201: Financial Performance of Harbin Pharmaceutical Group (in CNY Million), 2009-2013
  • Figure 202: Financial Performance of Jubilant Life Sciences (in INR Million), 2010-2014
  • Figure 203: Financial Performance of Sun Pharmaceutical Industries (in INR Million), 2010-2014

List of Tables

  • Table 1: Value of the Global Pharmaceutical Industry (in USD Billion), 2009-2013
  • Table 2: Segmentation of the Global Pharmaceutical Industry by Regions (in USD Billion & %), 2013
  • Table 3: Forecast of the Global Pharmaceutical Industry (in USD Billion), 2013-2018
  • Table 4: Value of the Global OTC Pharmaceutical Industry (in USD Million), 2009-2013
  • Table 5: Segmentation of the Global OTC Pharmaceutical Market by Categories (in USD Million & %), 2013
  • Table 6: Segmentation of the Global OTC Pharmaceutical Market by Regions (in USD Million & %), 2013
  • Table 7: Forecast of the Global OTC Pharmaceutical Industry (in USD Million), 2013-2018
  • Table 8: Value of the Global Generics Industry (in USD Million), 2009-2013
  • Table 9: Value of the Global Generics Industry (in USD Million), 2009-2013
  • Table 10: Generics Percentage of Total Pharmaceutical Volume & Market Volume of Global Generics Industry (%), 2009-2013
  • Table 11: Global Generics Industry, Segmentation by Geography (in USD Million), 2013
  • Table 12: Major Patent Expiries due by 2014
  • Table 13: Patent Expiries for Leading Biologic Drugs, 2010-2016
  • Table 14: Global Generics Industry Forecast (in USD Million), 2013-2018
  • Table 15: Global Generics Industry Forecast by Volume & Percentage Growth (%), 2013-2018
  • Table 16: Success Rates at Different R&D Stages
  • Table 17: Liability from Unintended Side Effects
  • Table 18: Pros & Cons of Three Types of Offshoring Models
  • Table 19: Leading Multinational & Domestic Pharmaceutical Companies by Market Share in China and India
  • Table 20: Value of the Pharmaceutical Industry in Australia (in USD Billion), 2009-2013
  • Table 21: Share of Australia in the Asia Pacific Pharmaceutical Industry (in USD Billion & %), 2013
  • Table 22: Forecast of the Pharmaceutical Industry in Australia (in USD Billion), 2013-2018
  • Table 23: Value of the Pharmaceutical Industry in Belgium (in USD Billion), 2009-2013
  • Table 24: Share of Belgium in the European Pharmaceutical Industry (in USD Billion & %), 2013
  • Table 25: Forecast of the Pharmaceutical Industry in Belgium (in USD Billion), 2013-2018
  • Table 26: Value of the Pharmaceutical Industry in Brazil (in USD Billion), 2009-2013
  • Table 27: Share of Brazil in the Americas Pharmaceutical Industry (in USD Billion & %), 2013
  • Table 28: Forecast of the Pharmaceutical Industry in Brazil (in USD Billion), 2013-2018
  • Table 29: Value of the Pharmaceutical Industry in Canada (in USD Billion), 2009-2013
  • Table 30: Share of Canada in the Americas Pharmaceutical Industry (in USD Billion & %), 2013
  • Table 31: Forecast of the Pharmaceutical Industry in Canada (in USD Billion), 2013-2018
  • Table 32: Value of the Pharmaceutical Industry in China (in USD Billion), 2009-2013
  • Table 33: Share of China in the Asia Pacific Pharmaceutical Industry (in USD Billion & %), 2013
  • Table 34: New Drug Classifications in China
  • Table 35: Top 10 Major Traditional Chinese Medicinal Materials, 2013
  • Table 36: Forecast of the Pharmaceutical Industry in China (in USD Billion), 2013-2018
  • Table 37: Value of the Pharmaceutical Industry in Czech Republic (in USD Billion), 2009-2013
  • Table 38: Share of Czech Republic in the European Pharmaceutical Industry (in USD Billion & %), 2013
  • Table 39: Forecast of the Czech Republic Pharmaceutical Industry (in USD Billion), 2013-2018
  • Table 40: Value of the Pharmaceutical Industry in Denmark (in USD Billion), 2009-2013
  • Table 41: Share of Denmark in the European Pharmaceutical Industry (in USD Billion & %), 2013
  • Table 42: Forecast of the Pharmaceutical Industry in Denmark (in USD Billion), 2013-2018
  • Table 43: Value of the Pharmaceutical Industry in France (in USD Billion), 2009-2013
  • Table 44: Share of France in the European Pharmaceutical Industry (in USD Billion & %), 2013
  • Table 45: Forecast of the Pharmaceutical Industry in France (in USD Billion), 2013-2018
  • Table 46: Value of the Pharmaceutical Industry in Germany (in USD Billion), 2009-2013
  • Table 47: Share of Germany in the European Pharmaceutical Industry (in USD Billion & %), 2013
  • Table 48: Forecast of the Pharmaceutical Industry in Germany (in USD Billion), 2013-2018
  • Table 49: Value of the Pharmaceutical Industry in Hungary (in USD Billion), 2009-2013
  • Table 50: Share of Hungary in the European Pharmaceutical Industry (in USD Billion & %), 2013
  • Table 51: Forecast of the Pharmaceutical Industry in Hungary (in USD Billion), 2013-2018
  • Table 52: Value of the Pharmaceutical Industry in India (in USD Billion), 2009-2013
  • Table 53: Share of India in the Asia Pacific Pharmaceutical Industry (in USD Billion & %), 2013
  • Table 54: Forecast of the Pharmaceutical Industry in India (in USD Billion), 2013-2018
  • Table 55: Value of the Pharmaceutical Industry in Italy (in USD Billion), 2009-2013
  • Table 56: Share of Italy in the European Pharmaceutical Industry (in USD Billion & %), 2013
  • Table 57: Forecast of the Pharmaceutical Industry in Italy (in USD Billion), 2013-2018
  • Table 58: Value of the Pharmaceutical Industry in Japan (in USD Billion), 2009-2013
  • Table 59: Share of Japan in the Asia Pacific Pharmaceutical Industry (in USD Billion & %), 2013
  • Table 60: Forecast of the Pharmaceutical Industry in Japan (in USD Billion), 2013-2018
  • Table 61: Value of the Pharmaceutical Industry in Mexico (in USD Billion), 2009-2013
  • Table 62: Share of Mexico in the Americas Pharmaceutical Industry (in USD Billion & %), 2013
  • Table 63: Forecast of the Pharmaceutical Industry in Mexico (in USD Billion), 2013-2018
  • Table 64: Value of the Dutch Pharmaceutical Industry (in USD Billion), 2009-2013
  • Table 65: Share of Netherlands in the European Pharmaceutical Industry (in USD Billion & %), 2013
  • Table 66: Forecast of the Netherlands Pharmaceutical Industry (in USD Billion), 2013-2018
  • Table 67: Value of the New Zealand Pharmaceutical Industry (in USD Billion), 2009-2013
  • Table 68: Share of New Zealand in the Asia Pacific Pharmaceutical Industry (in USD Billion & %), 2013
  • Table 69: Forecast of the New Zealand Pharmaceutical Industry (in USD Billion), 2013-2018
  • Table 70: Value of the Pharmaceutical Industry in Norway (in USD Billion), 2009-2013
  • Table 71: Share of Norway in the European Pharmaceutical Industry (in USD Billion & %), 2013
  • Table 72: Value of the Pharmaceutical Industry in Norway (in USD Billion), 2009-2013
  • Table 73: Value of the Pharmaceutical Industry in Poland (in USD Billion), 2009-2013
  • Table 74: Share of Poland in the European Pharmaceutical Industry (in USD Billion & %), 2013
  • Table 75: Forecast of the Pharmaceutical Industry in Poland (in USD Billion), 2013-2018
  • Table 76: Value of the Pharmaceutical Industry in Russia (in USD Billion), 2009-2013
  • Table 77: Share of Russia in the European Pharmaceutical Industry (in USD Billion & %), 2013
  • Table 78: Forecast of the Pharmaceutical Industry in Russia (in USD Billion), 2013-2018
  • Table 79: Value of the Pharmaceutical Industry in Singapore (in USD Billion), 2009-2013
  • Table 80: Share of Singapore in the Asia Pacific Pharmaceutical Industry (in USD Billion & %), 2013
  • Table 81: Forecast of the Pharmaceutical Industry in Singapore (in USD Billion), 2013-2018
  • Table 82: Value of the Pharmaceutical Industry in South Africa (in USD Billion), 2009-2013
  • Table 83: Share of South Africa in the MEA Pharmaceutical Industry (in USD Billion & %), 2013
  • Table 84: Forecast of the Pharmaceutical Industry in South Africa (in USD Billion), 2013-2018
  • Table 85: Value of the Pharmaceutical Industry in South Korea (in USD Billion), 2009-2013
  • Table 86: Share of South Korea in the Asia Pacific Pharmaceutical Industry (in USD Billion & %), 2013
  • Table 87: Forecast of the Pharmaceutical Industry in South Korea (in USD Billion), 2013-2018
  • Table 88: Value of the Pharmaceutical Industry in Spain (in USD Billion), 2009-2013
  • Table 89: Share of Spain in the European Pharmaceutical Industry (in USD Billion & %), 2013
  • Table 90: Forecast of the Pharmaceutical Industry in Spain (in USD Billion), 2013-2018
  • Table 91: Value of the Pharmaceutical Industry in Sweden (in USD Billion), 2009-2013
  • Table 92: Share of Sweden in the European Pharmaceutical Industry (in USD Billion & %), 2013
  • Table 93: Forecast of the Pharmaceutical Industry in Sweden (in USD Billion), 2013-2018
  • Table 94: Value of the Pharmaceutical Industry in Taiwan (in USD Billion), 2009-2013
  • Table 95: Share of Taiwan in the Asia Pacific Pharmaceutical Industry (in USD Billion & %), 2013
  • Table 96: Forecast of the Pharmaceutical Industry in Taiwan (in USD Billion), 2013-2018
  • Table 97: Value of the Pharmaceutical Industry in UK (in USD Billion), 2009-2013
  • Table 98: Share of UK in the European Pharmaceutical Industry (in USD Billion & %), 2013
  • Table 99: Forecast of the UK Pharmaceutical Industry (in USD Billion), 2013-2018
  • Table 100: Value of the US Pharmaceutical Industry (in USD Billion), 2009-2013
  • Table 101: Share of United States in the Global Pharmaceutical Industry (in USD Billion & %), 2013
  • Table 102: Forecast of the US Pharmaceutical Industry (in USD Billion), 2013-2018
  • Table 103: Abbott Laboratories Capital Market Ratios
  • Table 104: Abbott Laboratories Annual Ratios, 2009-2013
  • Table 105: Abbott Laboratories Quarterly Ratios, Sep 2013-Sep 2014
  • Table 106: Allergan, Inc. Capital Market Ratios
  • Table 107: Allergan, Inc. Annual Ratios, 2009-2013
  • Table 108: Allergan, Inc. Quarterly Ratios, Sep 2013-Sep 2014
  • Table 109: Amgen Capital Market Ratios
  • Table 110: Amgen Annual Ratios, 2009-2013
  • Table 111: Amgen Quarterly Ratios, Sep 2013-Sep 2014
  • Table 112: Aspen Pharmacare Capital Market Ratios
  • Table 113: Aspen Pharmacare Annual Ratios, 2010-2014
  • Table 114: Aspen Pharmacare Quarterly Ratios, June 2012-June 2014
  • Table 115: Astellas Pharma Capital Market Ratios
  • Table 116: Astellas Pharma Annual Ratios, 2010-2014
  • Table 117: Astellas Pharma Quarterly Ratios, Sep 2013-Sep 2014
  • Table 118: AstraZeneca Plc Capital Market Ratios
  • Table 119: AstraZeneca Plc Annual Ratios, 2009-2013
  • Table 120: AstraZeneca Plc Quarterly Ratios, Sep 2013-Sep 2014
  • Table 121: Baxter International Capital Market Ratios
  • Table 122: Baxter International Annual Ratios, 2009-2013
  • Table 123: Baxter International Quarterly Ratios, Sep 2013-Sep 2014
  • Table 124: Bayer AG Capital Market Ratios
  • Table 125: Bayer AG Annual Ratios, 2009-2013
  • Table 126: Bayer AG Quarterly Ratios, Sep 2013-Sep 2014
  • Table 127: Bristol-Myers Squibb Capital Market Ratios
  • Table 128: Bristol-Myers Squibb Annual Ratios, 2009-2013
  • Table 129: Bristol-Myers Squibb Quarterly Ratios, Sep 2013-Sep 2014
  • Table 130: Chugai Pharmaceutical Capital Market Ratios
  • Table 131: Chugai Pharmaceutical Annual Ratios, 2009-2013
  • Table 132: Chugai Pharmaceutical Quarterly Ratios, Sep 2013-Sep 2014
  • Table 133: Daewoong Pharmaceutical Capital Market Ratios
  • Table 134: Daewoong Pharmaceutical Annual Ratios, 2009-2013
  • Table 135: Daewoong Pharmaceutical Quarterly Ratios, Sep 2013-Sep 2014
  • Table 136: Daiichi Sankyo Company Capital Market Ratios
  • Table 137: Daiichi Sankyo Company Annual Ratios, 2010-2014
  • Table 138: Daiichi Sankyo Company Quarterly Ratios, Sep 2013-Sep 2014
  • Table 139: Eisai Co. Capital Market Ratios
  • Table 140: Eisai Co. Annual Ratios, 2010-2014
  • Table 141: Eisai Co. Quarterly Ratios, Sep 2013-Sep 2014
  • Table 142: Eli Lilly and Company Capital Market Ratios
  • Table 143: Eli Lilly and Company Annual Ratios, 2009-2013
  • Table 144: Eli Lilly and Company Quarterly Ratios, Sep 2013-Sep 2014
  • Table 145: F. Hoffmann-La Roche Capital Market Ratios
  • Table 146: F. Hoffmann-La Roche Annual Ratios, 2009-2013
  • Table 147: F. Hoffmann-La Roche Quarterly Ratios
  • Table 148: GlaxoSmithKline Capital Market Ratios
  • Table 149: GlaxoSmithKline Annual Ratios, 2009-2013
  • Table 150: GlaxoSmithKline Quarterly Ratios, Sep 2013-Sep 2014
  • Table 151: Johnson & Johnson Capital Market Ratios
  • Table 152: Johnson & Johnson Annual Ratios, 2009-2013
  • Table 153: Johnson & Johnson Quarterly Ratios, Sep 2013-Sep 2014
  • Table 154: Lupin Capital Market Ratios
  • Table 155: Lupin Annual Ratios, 2010-2014
  • Table 156: Lupin Quarterly Ratios, Sep 2013-Sep 2014
  • Table 157: Merck & Co. Capital Market Ratios
  • Table 158: Merck & Co. Annual Ratios, 2009-2013
  • Table 159: Merck & Co. Quarterly Ratios, Sep 2013-Sep 2014
  • Table 160: Novartis AG Capital Market Ratios
  • Table 161: Novartis AG Annual Ratios, 2009-2013
  • Table 162: Novartis AG Quarterly Ratios, Sep 2013-Sep 2014
  • Table 163: Pfizer Capital Market Ratios
  • Table 164: Pfizer Annual Ratios, 2009-2013
  • Table 165: Pfizer Quarterly Ratios, Sep 2013-Sep 2014
  • Table 166: Richter Gedeon Vegyeszeti Gyar Nyrt Capital Market Ratios
  • Table 167: Richter Gedeon Vegyeszeti Gyar Nyrt Annual Ratios, 2009-2013
  • Table 168: Richter Gedeon Vegyeszeti Gyar Nyrt Quarterly Ratios, Sep 2013-Sep 2014
  • Table 169: Sanofi SA Capital Market Ratios
  • Table 170: Sanofi SA Annual Ratios, 2009-2013
  • Table 171: Sanofi SA Quarterly Ratios, Sep 2013-Sep 2014
  • Table 172: Shanghai Pharmaceuticals Capital Market Ratios
  • Table 173: Shanghai Pharmaceuticals Annual Ratios, 2009-2013
  • Table 174: Shanghai Pharmaceuticals Quarterly Ratios, Sep 2013-Sep 2014
  • Table 175: Sumitomo Dainippon Pharma Capital Market Ratios
  • Table 176: Sumitomo Dainippon Pharma Annual Ratios, 2010-2014
  • Table 177: Sumitomo Dainippon Pharma Quarterly Ratios, Sep 2013-Sep 2014
  • Table 178: Takeda Pharmaceutical Company Capital Market Ratios
  • Table 179: Takeda Pharmaceutical Company Annual Ratios, 2010-2014
  • Table 180: Takeda Pharmaceutical Company Quarterly Ratios, Sep 2013-Sep 2014
  • Table 181: Teva Pharmaceutical Industries Capital Market Ratios
  • Table 182: Teva Pharmaceutical Industries Annual Ratios, 2009-2013
  • Table 183: Teva Pharmaceutical Industries Quarterly Ratios, Sep 2013-Sep 2014
  • Table 184: Aurobindo Pharma Capital Market Ratios
  • Table 185: Aurobindo Pharma Annual Ratios, 2010-2014
  • Table 186: Aurobindo Pharma Quarterly Ratios, June 2013-June 2014
  • Table 187: Cadila Healthcare Capital Market Ratios
  • Table 188: Cadila Healthcare Annual Ratios, 2010-2014
  • Table 189: Cadila Healthcare Quarterly Ratios, Sep 2013-Sep 2014
  • Table 190: China National Accord Medicines Corporation Capital Market Ratios
  • Table 191: China National Accord Medicines Corporation Annual Ratios, 2008-2012
  • Table 192: China National Accord Medicines Corporation Quarterly Ratios, Sep 2012-Sep 2013
  • Table 193: Cipla Ltd. Capital Market Ratios
  • Table 194: Cipla Ltd. Annual Ratios, 2010-2014
  • Table 195: Cipla Ltd. Quarterly Ratios, Sep 2013-Sep 2014
  • Table 196: Dr. Reddy's Laboratories Capital Market Ratios
  • Table 197: Dr. Reddy's Laboratories Annual Ratios, 2010-2014
  • Table 198: Hanmi Science Co Ltd Capital Market Ratios
  • Table 199: Hanmi Science Co Ltd Annual Ratios, 2009-2013
  • Table 200: Hanmi Science Co Ltd Quarterly Ratios, Sep 2013-Sep 2014
  • Table 201: Harbin Pharmaceutical Group Capital Market Ratios
  • Table 202: Harbin Pharmaceutical Group Annual Ratios, 2009-2013
  • Table 203: Harbin Pharmaceutical Group Quarterly Ratios, Sep 2013-Sep 2014
  • Table 204: Jubilant Life Sciences Capital Market Ratios
  • Table 205: Jubilant Life Sciences Annual Ratios, 2010-2014
  • Table 206: Jubilant Life Sciences Quarterly Ratios, Sep 2013-Sep 2014
  • Table 207: Pharmstandard Capital Market Ratios
  • Table 208: Pharmstandard Annual Ratios, 2006-2010
  • Table 209: Pharmstandard Quarterly Ratios, Sep 2013-Sep 2014
  • Table 210: Ranbaxy Laboratories Capital Market Ratios
  • Table 211: Ranbaxy Laboratories Annual Ratios, 2010-2014
  • Table 212: Ranbaxy Laboratories Quarterly Ratios, Sep 2013-Sep 2014
  • Table 213: Sun Pharmaceutical Industries Capital Market Ratios
  • Table 214: Sun Pharmaceutical Industries Annual Ratios, 2010-2014
  • Table 215: Sun Pharmaceutical Industries Quarterly Ratios, Sep 2013-Sep 2014
Back to Top